clinical trial · NCT05594589
A Study to Assess the Pharmacodynamics of Lemborexant in Korean Participants With Insomnia Disorder
Eisai Co., Ltd.·phase2·completed·n = 65
Sleep Initiation and Maintenance DisordersLemborexantPBO
brief summary
The primary purpose of the study is to evaluate the treatment difference between lemborexant 5 milligram (mg) (LEM5) and placebo (PBO) on latency to persistent sleep (LPS) using polysomnography (PSG) on Day 30.
started
Nov 30, 2022
primary completion
Apr 26, 2024
completion
May 24, 2024
last updated
Jul 3, 2025
official title
A Multicenter, Double-Blind, Randomized, Placebo-Controlled, Parallel-Group Study to Assess the Pharmacodynamics of Lemborexant in Korean Subjects With Insomnia Disorder
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol